Corrigendum to “Phase II study of a trastuzumab biosimilar in combination with paclitaxel for HER2-positive recurrent or metastatic urothelial carcinoma: KCSG GU18-18”: [ESMO Open 8 (2023) 101588] (ESMO Open (2023) 8(4), (S2059702923008220), (10.1016/j.esmoop.2023.101588))

초록

The authors regret that in the original publication under PATIENTS AND METHODS details of the registration of the study were given incorrectly: The sentence “The study was reviewed and approved by the research board of each participating institution and is registered at ClinicalTrials.gov (NCT03698383).” should read “The study was reviewed and approved by the research board of each participating institution and is registered at the Korean Disease Control and Prevention Agency's Clinical Information Service (cris.nih.go.kr; KCT0003543).” The authors would like to apologise for any inconvenience caused. © 2024 The Author(s)